Synthesis of novel pyrimidine-based Schiff base complexes: Targeting Amyloid-β aggregation in Alzheimer's disease.

A novel Schiff base with imine/amine donors, 5-((3,3-diphenylalilidene)amino)pyrimidine-4-amine (L), and its new Platinum(II) and Ruthenium(II) complexes (I and II) were synthesized and characterized using FT-IR, H NMR, C NMR, mass spectrometry and elemental analyses. The ability of these complexes to inhibit amyloid beta (Aβ) aggregation was evaluated using the human neuroblastoma cell line (SH-SY5Y). The complexes effectively inhibited Aβ aggregation at a 1:1 M ratio. Both complexes increased cell viability up to 80 % at concentrations of 10 μM. At this concentration, the cell viability value found by Aβ aggregation is around 65 %. Aggregation kinetics were fluorometrically monitored using Thioflavin T. These findings were further supported by scanning electron microscopy and transmission electron microscopy. In addition, the interaction of the complexes with Aβ was investigated using MALDI-TOF/MS and H NMR spectroscopy. All findings showed that Aβ in both complexes is active in the inhibition of amyloid aggregation.